Published in Am J Clin Exp Urol on October 02, 2014
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res (1999) 3.79
Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
ETS rearrangements and prostate cancer initiation. Nature (2009) 1.58
A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol (2012) 1.42
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest (2013) 1.38
Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest (1998) 1.35
ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol (2011) 1.31
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol (2011) 1.26
The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res (2010) 1.09
The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol (2001) 1.07
ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch (2011) 1.04
Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line. Cancer Res (2001) 0.99
Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells. Transl Oncol (2010) 0.99
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment. Cancer Epidemiol Biomarkers Prev (2014) 0.95
ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS One (2014) 0.89
ETS fusion genes in prostate cancer. Endocr Relat Cancer (2014) 0.89
TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate (2011) 0.88
Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2014) 0.88
Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate (2013) 0.86
TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry. Histopathology (2013) 0.86
Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression. Hum Pathol (2012) 0.83
Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer. BMC Med Genomics (2014) 0.83
Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing? Clin Cancer Res (2014) 0.83
ETS gene fusions and prostate cancer. Am J Transl Res (2009) 0.80
Distinguishing indolent from aggressive prostate cancer. Recent Results Cancer Res (2014) 0.76